stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Net income
Ascendis Pharma A/S's net income for fiscal 2025 was −$258.0M, compared with −$409.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $865.9M. Over the past ten years it has ranged from −$614.5M (fiscal 2022) to −$36.6M (fiscal 2015); the current reading is higher than 55% of that period. Net income has risen for 3 consecutive fiscal years. Ascendis Pharma A/S ranks 10th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$258.0M | — |
| FY2024 | −$409.1M | — |
| FY2023 | −$521.1M | — |
| FY2022 | −$614.5M | — |
| FY2021 | −$453.8M | — |
| FY2020 | −$478.6M | — |
| FY2019 | −$244.2M | — |
| FY2018 | −$153.6M | — |
| FY2017 | −$140.0M | — |
| FY2016 | −$75.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $235.8M | (67.99%) |
| Mar 2026 | $736.6M | — |
| Dec 2025 | −$30.7M | — |
| Sep 2025 | −$75.8M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S | $865.9M |
| HALO Halozyme Therapeutics, Inc. compare | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ASND
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement